According to research presented to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), using a scan for prostate cancer therapy can help in personalizing the treatment. In the two cycles of 177Lu-PSMA radioligand, the study found that prostate-specific membrane antigen (PSMA) PET imaging can help predict survival.
Here are the details of the prostate cancer therapy tailored treatment:
- Use of PSMA avid tumor volume to assess tumor response after two RLT cycles is highly associated with patient survival. The National Cancer Institute (NCI) statistics show survival rates of metastatic cancer patients at 30.5%. The phase two trial that involved treatment of patients using 177Lu-PSMA therapy had promising results. Selection of patients for radioligand therapy is made explicitly through preliminary PSMA PET scan to check eligibility for lymphoma patients. It produced positive results.
- Analysis of patients at baseline who underwent gallium-68 (68Ga)-PSMA 11PET/CT after two cycles of 177Lu PSMA RLT to check the risk of prostate cancer survival. It substitutes the traditional standardized uptake in evaluating the body tumor burden. Results indicate that interim PSMA PET is useful for patients undergoing therapeutic response assessment through the use of 177Lu PSMA RLT.
PSMA PET CT scan has many benefits for prostate cancer patients. Those benefits include:
- It provides an accurate diagnosis of prostate cancer.
- Enables earlier suspicion and evaluation of prostate cancer, which will improve treatment response evaluation.
- The technology produces high quality images for proper diagnosis and treatment of prostate cancer.
- It is used to check the Serum PSA level in prostate patients to identify changes of prostate cancer reoccurrence.
Further analysis using clinical parameters will give patients higher chances of success. PSMA PET CT scan ensures the use of high-quality technology for treatment, which will provide patients with better outcomes. The technology is trusted in provide the right images for diagnosis.